DDIT3 and mantle cell lymphoma: With a median follow-up of 13.4 years, we were able to demonstrate a statistically significant benefit in FFS, OS and DOR for R-CHOP compared to CHOP, adding further evidence to the existing literature and underlining the positive effect of rituximab in first line MCL therapy (Fig. 2).